With $50 million from Japanese firm NEC, biomedical software startup BostonGene seeks to assess patients' "immune fitness" in the quest for better therapies.
The year-old Princess Máxima Center, based in Utrecht, has turned to bioinformatics firm The Hyve to address integration and interoperability issues.
The effort, called FAIRplus, commenced earlier this year with a budget of €8.2 million, funded by the Innovative Medicine Initiative.
Ardigen has expanded into immuno-oncology, microbiomics, epigenomics, and CRISPR data analysis to support drug development and precision medicine.
At Bio-IT World, Sage Bionetworks' John Wilbanks called on the research community to adopt the OMOP and FHIR standards so data becomes more useful to other scientists.
The informatics firms signed agreements to offer certain of their genomic data technologies on Google's cloud-based computing services platform.
Proposals from two HHS agencies look to encourage patient access to data and interoperability in research and clinical practice, including Sync for Genes.
Funded by a $120M grant, the planned interdisciplinary School of Data Science will dedicate perhaps a quarter of its resources to bioinformatics-related activities.
LunaDNA parent company LunaPBS will combine its technology platform with Genetic Alliance's PEER system to advance patient-centric research.
This embargo-free strategy represents "an entirely new way of doing research" into rare pediatric cancers, where time is of the essence.
University of Idaho researchers model the scientific discovery process to examine the link between reproducibility and scientific truth.
A bill passed by a US House of Representatives appropriations subcommittee would give scientific agencies including the National Science Foundation boosts in funding.
Relocating USDA agencies outside of Washington, DC, may make them less effective, critics of the move tell NPR.
In PLOS this week: genes that help Borrelia burgdorferi survive in ticks, CiliaCarta collection of about 1,000 suspected cilia genes, and more.